ZOMETA® has a well-characterised safety profile across multiple malignancies
ZOMETA renal safety profile in various malignancies
Breast cancer |
ZOMETA did not cause grade 3/4* serum creatinine elevations in a randomised, placebo-controlled clinical trial in patients with breast cancer3 |
Prostate cancer |
The incidence of grade 3* serum creatinine elevations in patients with prostate cancer was 3.3% for ZOMETA and 1.0% for placebo4
- No grade 4* serum creatinine elevations were observed
|
Lung cancer |
In patients with lung cancer or other solid tumours, the renal safety profile of ZOMETA has been shown to be similar to that of placebo (grade 3/4* serum creatinine elevations, 1.8% in both groups)5 |
Multiple myeloma |
ZOMETA 4 mg every 3 to 4 weeks by 15-minute infusion demonstrated a similar renal safety profile to that of pamidronate 90 mg every 3 to 4 weeks by 90-minute infusion (grade 3/4* serum creatinine elevations, 0.4% vs 1.9%, respectively)6 |
- ZOMETA 4 mg every 3 to 4 weeks has a well-characterised renal safety profile—even in patients who have had nephrectomies1,2
- — For patients whose renal function is impaired* due to renal cell carcinoma or other causes, the dose of ZOMETA can be adjusted to prevent safety issues1
*Grade 3 defined as >3x upper limit of normal (ULN); grade 4 defined as >6x ULN.
